(Q42033600)

15 October 2017

0 references

Overview of azathioprine treatment in multiple sclerosis (English)

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91909-E

27 October 2022

0 references

1 reference

3

A Ghezzi

1 reference

15 October 2017

P. L. Yudkin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1681364

27 October 2022

G. W. Ellison

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1681364

27 October 2022

D. E. Goodkin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1681364

27 October 2022

R. A. Hughes

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1681364

27 October 2022

K. McPherson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1681364

27 October 2022

J. Mertin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1681364

27 October 2022

C. Milanese

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1681364

27 October 2022

language of work or name

English

0 references

publication date

1 October 1991

1 reference

15 October 2017

26 October 1991

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1681364

full work available at URL

27 October 2022

https://api.elsevier.com/content/article/PII:014067369191909E?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91909-E

https://api.elsevier.com/content/article/PII:014067369191909E?httpAccept=text/plain

27 October 2022

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91909-E

27 October 2022

1 reference

15 October 2017

338

1 reference

15 October 2017

1051-1055

1 reference

15 October 2017

8774

1 reference

Why do we need systematic overviews of randomized trials?

15 October 2017

1

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91909-E

The Disability Status Scale for multiple sclerosis: apologia pro DSS sua.

27 October 2022

3

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91909-E

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

27 October 2022

4

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91909-E

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

27 October 2022

5

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91909-E

An illness severity score for multiple sclerosis

27 October 2022

7

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91909-E

Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone

27 October 2022

9

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91909-E

Long-term treatment of multiple sclerosis with azathioprine

27 October 2022

12

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91909-E

Prolonged azathioprine treatment of non-remitting multiple sclerosis

27 October 2022

13

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91909-E

Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: final report

27 October 2022

14

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91909-E

Azathioprine in treatment of multiple sclerosis. Final results of a 41/2-year controlled study of its effectiveness covering 115 patients

27 October 2022

15

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91909-E

Double blind controlled randomized study on azathioprine efficacy in multiple sclerosis. Preliminary results

27 October 2022

17

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91909-E

A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis

27 October 2022

20

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91909-E

The efficacy of azathioprine in relapsing-remitting multiple sclerosis

27 October 2022

21

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91909-E

The Combination of Estimates from Different Experiments

27 October 2022

22

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91909-E

Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.

27 October 2022

23

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91909-E

An assessment of disability rating scales used in multiple sclerosis.

27 October 2022

24

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91909-E

Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment

27 October 2022

26

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91909-E

27 October 2022

Identifiers

1 reference

15 October 2017

1 reference